Skip to main content
PMC home page
Neuroscience Bulletin logoLink to Neuroscience Bulletin
. 2014 May 16;30(3):515–523. doi: 10.1007/s12264-013-1439-3

Inflammation: a mechanism of depression?

Qiu-Qin Han 1, Jin Yu 1,✉
PMCID: PMC5562613  PMID: 24838302

Abstract

In recent decades, major depression has become more prevalent and research has shown that immune activation and cytokine production may be involved. This review is mainly focused on the contribution of inflammation to depression. We first briefly introduce the inflammatory biomarkers of depression, then discuss the sources of cytokines in the brain, and finally describe the neuroimmunological mechanisms underlying the association between inflammation and depression.

Keywords: depression, inflammation, cytokines, hypothalamic-pituitary-adrenal axis, 5-HT, neuroplasticity

References

  • [1].Compton WM, Conway KP, Stinson FS, Grant BF. Changes in the prevalence of major depression and comorbid substance use disorders in the United States between 1991–1992 and 2001–2002. Am J Psychiatry. 2006;163:2141–2147. doi: 10.1176/ajp.2006.163.12.2141. [DOI] [PubMed] [Google Scholar]
  • [2].Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: Lifetime prevalence, chronicity and recurrence. J Affect Disord. 1993;29:85–96. doi: 10.1016/0165-0327(93)90026-g. [DOI] [PubMed] [Google Scholar]
  • [3].Sharpley CF, Agnew LL. Cytokines and depression: findings, issues, and treatment implications. Rev Neurosci. 2011;22:295–302. doi: 10.1515/RNS.2011.030. [DOI] [PubMed] [Google Scholar]
  • [4].Dunn AJ, Swiergiel AH, de Beaurepaire R. Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev. 2005;29:891–909. doi: 10.1016/j.neubiorev.2005.03.023. [DOI] [PubMed] [Google Scholar]
  • [5].Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med. 2009;71:171–186. doi: 10.1097/PSY.0b013e3181907c1b. [DOI] [PubMed] [Google Scholar]
  • [6].Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095–2147. [PubMed] [Google Scholar]
  • [7].Plata-Salaman CR, Ilyin SE. Interleukin-1beta (IL-1beta)-induced modulation of the hypothalamic IL-1beta system, tumor necrosis factor-alpha, and transforming growth factorbeta1 mRNAs in obese (fa/fa) and lean (Fa/Fa) Zucker rats: implications to IL-1beta feedback systems and cytokine-cytokine interactions. J Neurosci Res. 1997;49:541–550. doi: 10.1002/(SICI)1097-4547(19970901)49:5<541::AID-JNR4>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  • [8].Kronfol Z, Remick DG. Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 2000;157:683–694. doi: 10.1176/appi.ajp.157.5.683. [DOI] [PubMed] [Google Scholar]
  • [9].Macaluso M, Drevets WC, Preskorn SH. How biomarkers will change psychiatry. Part II: Biomarker selection and potential inflammatory markers of depression. J Psychiatr Pract. 2012;18:281–286. doi: 10.1097/01.pra.0000416018.83709.3e. [DOI] [PubMed] [Google Scholar]
  • [10].Schmidt HD, Shelton RC, Duman RS. Functional biomarkers of depression: diagnosis, treatment, and pathophysiology. Neuropsychopharmacology. 2011;36:2375–2394. doi: 10.1038/npp.2011.151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [11].Taler M, Gil-Ad I, Lomnitski L, Korov I, Baharav E, Bar M, et al. Immunomodulatory effect of selective serotonin reuptake inhibitors (SSRIs) on human T lymphocyte function and gene expression. Eur Neuropsychopharmacol. 2007;17:774–780. doi: 10.1016/j.euroneuro.2007.03.010. [DOI] [PubMed] [Google Scholar]
  • [12].Sutcigil L, Oktenli C, Musabak U, Bozkurt A, Cansever A, Uzun O, et al. Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol. 2007;2007:76396. doi: 10.1155/2007/76396. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK, et al. A meta-analysis of cytokines in major depression. Biol Psychiatry. 2010;67:446–457. doi: 10.1016/j.biopsych.2009.09.033. [DOI] [PubMed] [Google Scholar]
  • [14].Kahl KG, Bens S, Ziegler K, Rudolf S, Dibbelt L, Kordon A, et al. Cortisol, the cortisol-dehydroepiandrosterone ratio, and pro-inflammatory cytokines in patients with current major depressive disorder comorbid with borderline personality disorder. Biol Psychiatry. 2006;59:667–671. doi: 10.1016/j.biopsych.2005.08.001. [DOI] [PubMed] [Google Scholar]
  • [15].Steptoe A, Hamer M, Chida Y. The effects of acute psychological stress on circulating inflammatory factors in humans: a review and meta-analysis. Brain Behav Immun. 2007;21:901–912. doi: 10.1016/j.bbi.2007.03.011. [DOI] [PubMed] [Google Scholar]
  • [16].Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006;27:24–31. doi: 10.1016/j.it.2005.11.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [17].Diniz BS, Teixeira AL, Talib L, Gattaz WF, Forlenza OV. Interleukin-1beta serum levels is increased in antidepressant-free elderly depressed patients. Am J Geriatr Psychiatry. 2010;18:172–176. doi: 10.1097/JGP.0b013e3181c2947f. [DOI] [PubMed] [Google Scholar]
  • [18].Yoshimura R, Hori H, Ikenouchi-Sugita A, Umene-Nakano W, Ueda N, Nakamura J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:722–726. doi: 10.1016/j.pnpbp.2009.03.020. [DOI] [PubMed] [Google Scholar]
  • [19].Himmerich H, Milenovic S, Fulda S, Plumakers B, Sheldrick AJ, Michel TM, et al. Regulatory T cells increased while IL-1beta decreased during antidepressant therapy. J Psychiatr Res. 2010;44:1052–1057. doi: 10.1016/j.jpsychires.2010.03.005. [DOI] [PubMed] [Google Scholar]
  • [20].Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) 2003;170:429–433. doi: 10.1007/s00213-003-1566-z. [DOI] [PubMed] [Google Scholar]
  • [21].Jazayeri S, Keshavarz SA, Tehrani-Doost M, Djalali M, Hosseini M, Amini H, et al. Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res. 2010;178:112–115. doi: 10.1016/j.psychres.2009.04.013. [DOI] [PubMed] [Google Scholar]
  • [22].Shelton RC, Miller AH. Inflammation in depression: is adiposity a cause? Dialogues Clin Neurosci. 2011;13:41–53. doi: 10.31887/DCNS.2011.13.1/rshelton. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [23].Wu XP, Wang D, Song ZJ, Sun CZ, Xiao XL, He YD, et al. [Impact of anxiety-depression symptoms on clinical recovery and serum TNF-alpha and IL-6 of patients with burns] Sichuan Da Xue Xue Bao Yi Xue Ban. 2008;39:105–107. [PubMed] [Google Scholar]
  • [24].Jehn CF, Kuhnhardt D, Bartholomae A, Pfeiffer S, Schmid P, Possinger K, et al. Association of IL-6, hypothalamus-pituitary-adrenal axis function, and depression in patients with cancer. Integr Cancer Ther. 2010;9:270–275. doi: 10.1177/1534735410370036. [DOI] [PubMed] [Google Scholar]
  • [25].Liu Y, Ho RC, Mak A. The role of interleukin (IL)-17 in anxiety and depression of patients with rheumatoid arthritis. Int J Rheum Dis. 2012;15:183–187. doi: 10.1111/j.1756-185X.2011.01673.x. [DOI] [PubMed] [Google Scholar]
  • [26].Cheng J, Zhang J, Lu C, Wang L. Using optogenetics to translate the “inflammatory dialogue” between heart and brain in the context of stress. Neurosci Bull. 2012;28:435–448. doi: 10.1007/s12264-012-1246-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Quan N, Banks WA. Br ain-immune communication pathways. Brain Behav Immun. 2007;21:727–735. doi: 10.1016/j.bbi.2007.05.005. [DOI] [PubMed] [Google Scholar]
  • [28].Krishnadas R, Cavanagh J. Depression: an inflammatory illness? J Neurol Neurosurg Psychiatry. 2012;83:495–502. doi: 10.1136/jnnp-2011-301779. [DOI] [PubMed] [Google Scholar]
  • [29].Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther. 2011;130:226–238. doi: 10.1016/j.pharmthera.2011.01.014. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [30].Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46–56. doi: 10.1038/nrn2297. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [31].Freidin M, Bennett MV, Kessler JA. Cultured sympathetic neurons synthesize and release the cytokine interleukin 1 beta. Proc Natl Acad Sci U S A. 1992;89:10440–10443. doi: 10.1073/pnas.89.21.10440. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [32].Breder CD, Tsujimoto M, Terano Y, Scott DW, Saper CB. Distribution and characterization of tumor necrosis factor-alpha-like immunoreactivity in the murine central nervous system. J Comp Neurol. 1993;337:543–567. doi: 10.1002/cne.903370403. [DOI] [PubMed] [Google Scholar]
  • [33].Bethea JR, Chung IY, Sparacio SM, Gillespie GY, Benveniste EN. Interleukin-1 beta induction of tumor necrosis factor-alpha gene expression in human astroglioma cells. J Neuroimmunol. 1992;36:179–191. doi: 10.1016/0165-5728(92)90049-q. [DOI] [PubMed] [Google Scholar]
  • [34].Juul SE, Anderson DK, Li Y, Christensen RD. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr Res. 1998;43:40–49. doi: 10.1203/00006450-199801000-00007. [DOI] [PubMed] [Google Scholar]
  • [35].Tweardy DJ, Mott PL, Glazer EW. Monokine modulation of human astroglial cell production of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. I. Effects of IL-1 alpha and IL-beta. J Immunol. 1990;144:2233–2241. [PubMed] [Google Scholar]
  • [36].Breder CD, Dinarello CA, Saper CB. Interleukin-1 immunoreactive innervation of the human hypothalamus. Science. 1988;240:321–324. doi: 10.1126/science.3258444. [DOI] [PubMed] [Google Scholar]
  • [37].Rothwell NJ, Luheshi G. Pharma cology of interleukin-1 actions in the brain. Adv Pharmacol. 1994;25:1–20. doi: 10.1016/s1054-3589(08)60428-7. [DOI] [PubMed] [Google Scholar]
  • [38].Hanisch UK, Quirion R. Interleu kin-2 as a neuroregulatory cytokine. Brain Res Brain Res Rev. 1995;21:246–284. doi: 10.1016/0165-0173(95)00015-1. [DOI] [PubMed] [Google Scholar]
  • [39].Konishi Y, Chui DH, Kunishita T, Yamamura T, Higashi Y, Tabira T. Demonstration of interleukin-3 receptor-associated antigen in the central nervous system. J Neurosci Res. 1995;41:572–582. doi: 10.1002/jnr.490410503. [DOI] [PubMed] [Google Scholar]
  • [40].Racke MK, Burnett D, Pak SH, Albert PS, Cannella B, Raine CS, et al. Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with improved disease course. J Immunol. 1995;154:450–458. [PubMed] [Google Scholar]
  • [41].Benveniste EN, Sparacio SM, Norris JG, Grenett HE, Fuller GM. Induction and regulation of interleukin-6 gene expression in rat astrocytes. J Neuroimmunol. 1990;30:201–212. doi: 10.1016/0165-5728(90)90104-u. [DOI] [PubMed] [Google Scholar]
  • [42].Ehrlich LC, Hu S, Sheng WS, Sutton RL, Rockswold GL, Peterson PK, et al. Cytokine regulation of human microglial cell IL-8 production. J Immunol. 1998;160:1944–1948. [PubMed] [Google Scholar]
  • [43].Wong ML, Bongiorno PB, Rettori V, McCann SM, Licinio J. Interleukin (IL) 1beta, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: pathophysiological implications. Proc Natl Acad Sci U S A. 1997;94:227–232. doi: 10.1073/pnas.94.1.227. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [44].Stalder AK, Pagenstecher A, Yu NC, Kincaid C, Chiang CS, Hobbs MV, et al. Lipopolysaccharide-induced IL-12 expression in the central nervous system and cultured astrocytes and microglia. J Immunol. 1997;159:1344–1351. [PubMed] [Google Scholar]
  • [45].Bethea JR, Gillespie GY, Benveniste EN. Interleukin-1 beta induction of TNF-alpha gene expression: involvement of protein kinase C. J Cell Physiol. 1992;152:264–273. doi: 10.1002/jcp.1041520207. [DOI] [PubMed] [Google Scholar]
  • [46].Tilders FJ, DeRijk RH, Van Dam AM, Vincent VA, Schotanus K, Persoons JH. Activation of the hypothalamus-pituitary-adrenal axis by bacterial endotoxins: routes and intermediate signals. Psychoneuroendocrinology. 1994;19:209–232. doi: 10.1016/0306-4530(94)90010-8. [DOI] [PubMed] [Google Scholar]
  • [47].Monje FJ, Cabatic M, Divisch I, Kim EJ, Herkner KR, Binder BR, et al. Constant darkness induces IL-6-dependent depression-like behavior through the NF-kappaB signaling pathway. J Neurosci. 2011;31:9075–9083. doi: 10.1523/JNEUROSCI.1537-11.2011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [48].Marini H, Altavilla D, Bellomo M, Adamo E B, Marini R, Laureanti F, et al. Modulation of IL-1 beta gene expression by lipid peroxidation inhibition after kainic acid-induced rat brain injury. Exp Neurol. 2004;188:178–186. doi: 10.1016/j.expneurol.2004.03.023. [DOI] [PubMed] [Google Scholar]
  • [49].Kumagai N, Chiba Y, Hosono M, Fujii M, Kawamura N, Keino H, et al. Involvement of pro-inflammatory cytokines and microglia in an age-associated neurodegeneration model, the SAMP10 mouse. Brain Res. 2007;1185:75–85. doi: 10.1016/j.brainres.2007.09.021. [DOI] [PubMed] [Google Scholar]
  • [50].Feuerstein GZ, Wang X, Barone FC. Inflammat ory gene expression in cerebral ischemia and trauma. Potential new therapeutic targets. Ann N Y Acad Sci. 1997;825:179–193. doi: 10.1111/j.1749-6632.1997.tb48428.x. [DOI] [PubMed] [Google Scholar]
  • [51].Minami M, Kuraishi Y, Satoh M. Effects of ka inic acid on messenger RNA levels of IL-1 beta, IL-6, TNF alpha and LIF in the rat brain. Biochem Biophys Res Commun. 1991;176:593–598. doi: 10.1016/s0006-291x(05)80225-6. [DOI] [PubMed] [Google Scholar]
  • [52].Siren AL, Heldman E, Doron D, Lysko PG, Yue T L, Liu Y, et al. Release of proinflammatory and prothrombotic mediators in the brain and peripheral circulation in spontaneously hypertensive and normotensive Wistar-Kyoto rats. Stroke. 1992;23:1643–1650. doi: 10.1161/01.str.23.11.1643. [DOI] [PubMed] [Google Scholar]
  • [53].Alvarez XA, Franco A, Fernandez-Novoa L, Cacabelos R. Effects of neurotoxic lesions in histaminergic neurons on brain tumor necrosis factor levels. Agents Actions. 1994;41Spec:C70–72. doi: 10.1007/BF02007772. [DOI] [PubMed] [Google Scholar]
  • [54].Shohami E, Novikov M, Bass R, Yamin A, Gallily R. Closed head injury triggers early production of TNF alpha and IL-6 by brain tissue. J Cereb Blood Flow Metab. 1994;14:615–619. doi: 10.1038/jcbfm.1994.76. [DOI] [PubMed] [Google Scholar]
  • [55].Taupin V, Toulmond S, Serrano A, Benavides J, Zavala F. Increase in IL-6, IL-1 and TNF levels in rat brain following traumatic lesion. Influence of pre- and post-traumatic treatment with Ro5 4864, a peripheral-type (p site) benzodiazepine ligand. J Neuroimmunol. 1993;42:177–185. doi: 10.1016/0165-5728(93)90008-m. [DOI] [PubMed] [Google Scholar]
  • [56].van der Werf-Eldering MJ, Riemersma-van der Lek R F, Burger H, Holthausen EA, Aleman A, Nolen WA. Can variation in hypothalamic-pituitary-adrenal (HPA)-axis activity explain the relationship between depression and cognition in bipolar patients? PLoS One. 2012;7:e37119. doi: 10.1371/journal.pone.0037119. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [57].Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab. 1993;77:1690–1694. doi: 10.1210/jcem.77.6.8263159. [DOI] [PubMed] [Google Scholar]
  • [58].Himmerich H, Binder EB, Kunzel HE, Schuld A, Lucae S, Uhr M, et al. Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry. 2006;60:882–888. doi: 10.1016/j.biopsych.2006.03.075. [DOI] [PubMed] [Google Scholar]
  • [59].O’Keane V, Frodl T, Dinan TG. A review of Atypical depression in relation to the course of depression and changes in HPA axis organization. Psychoneuroendocrinology. 2012;37:1589–1599. doi: 10.1016/j.psyneuen.2012.03.009. [DOI] [PubMed] [Google Scholar]
  • [60].Frost P, Bornstein S, Ehrhart-Bornstein M, O’Kirwan F, Hutson C, Heber D, et al. The prototypic antidepressant drug, imipramine, but not Hypericum perforatum (St. John’s Wort), reduces HPA-axis function in the rat. Horm Metab Res. 2003;35:602–606. doi: 10.1055/s-2003-43507. [DOI] [PubMed] [Google Scholar]
  • [61].Myint AM, Kim YK. Cytokine-serotonin interaction thro ugh IDO: a neurodegeneration hypothesis of depression. Med Hypotheses. 2003;61:519–525. doi: 10.1016/s0306-9877(03)00207-x. [DOI] [PubMed] [Google Scholar]
  • [62].Catena-Dell’Osso M, Rotella F, Dell’Osso A, Fagiolini A, Marazziti D. Inflammation, serotonin and major depression. Curr Drug Targets. 2013;14:571–577. doi: 10.2174/13894501113149990154. [DOI] [PubMed] [Google Scholar]
  • [63].Pemberton LA, Kerr SJ, Smythe G, Brew BJ. Quinolinic ac id production by macrophages stimulated with IFN-gamma, TNF-alpha, and IFN-alpha. J Interferon Cytokine Res. 1997;17:589–595. doi: 10.1089/jir.1997.17.589. [DOI] [PubMed] [Google Scholar]
  • [64].Fujigaki S, Saito K, Sekikawa K, Tone S, Takikawa O, Fujii H, et al. Lipopolysaccharide induction of indoleamine 2,3-dioxygenase is mediated dominantly by an IFN-gamma-independent mechanism. Eur J Immunol. 2001;31:2313–2318. doi: 10.1002/1521-4141(200108)31:8<2313::aid-immu2313>3.0.co;2-s. [DOI] [PubMed] [Google Scholar]
  • [65].Wichers MC, Maes M. The role of indoleamine 2,3-dioxy gena se (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci. 2004;29:11–17. [PMC free article] [PubMed] [Google Scholar]
  • [66].Heyes MP, Saito K, Crowley JS, Davis LE, Demitrack MA, Der M, et al. Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease. Brain. 1992;115(Pt5):1249–1273. doi: 10.1093/brain/115.5.1249. [DOI] [PubMed] [Google Scholar]
  • [67].Wichers M, Maes M. The psychoneuroimmuno-patho physiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol. 2002;5:375–388. doi: 10.1017/S1461145702003103. [DOI] [PubMed] [Google Scholar]
  • [68].Dantzer R. Cytokine, sickness behavior, and depression. Immu nol Allergy Clin North Am. 2009;29:247–264. doi: 10.1016/j.iac.2009.02.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [69].Sublette ME, Postolache TT. Neuroinflammation and depression: the role of indoleamine 2,3-dioxygenase (IDO) as a molecular pathway. Psychosom Med. 2012;74:668–672. doi: 10.1097/PSY.0b013e318268de9f. [DOI] [PubMed] [Google Scholar]
  • [70].Prendergast GC, Chang MY, Mandik-Nayak L, Metz R, Muller AJ. I ndoleamine 2,3-dioxygenase as a modifier of pathogenic inflammation in cancer and other inflammation-associated diseases. Curr Med Chem. 2011;18:2257–2262. doi: 10.2174/092986711795656072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [71].Lesch KP, Mossner R. Genetically driven variation in serotonin uptake: is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry. 1998;44:179–192. doi: 10.1016/s0006-3223(98)00121-8. [DOI] [PubMed] [Google Scholar]
  • [72].Staley JK, Malison RT, Innis RB. Imaging of the serotonergic sys tem: interactions of neuroanatomical and functional abnormalities of depression. Biol Psychiatry. 1998;44:534–549. doi: 10.1016/s0006-3223(98)00185-1. [DOI] [PubMed] [Google Scholar]
  • [73].Tsao CW, Lin YS, Chen CC, Bai CH, Wu SR. Cytokines and serotonin transporter in patients with major depression. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30:899–905. doi: 10.1016/j.pnpbp.2006.01.029. [DOI] [PubMed] [Google Scholar]
  • [74].Morikawa O, Sakai N, Obara H, Saito N. Effects of interferon-alpha, interferon-gamma and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol. 1998;349:317–324. doi: 10.1016/s0014-2999(98)00187-3. [DOI] [PubMed] [Google Scholar]
  • [75].Mossner R, Heils A, Stober G, Okladnova O, Daniel S, Lesch KP. Enha ncement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6. Neurochem Int. 1998;33:251–254. doi: 10.1016/s0197-0186(98)00026-6. [DOI] [PubMed] [Google Scholar]
  • [76].Abe S, Hori T, Suzuki T, Baba A, Shiraishi H, Yamamoto T. Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain. Neurochem Res. 1999;24:359–363. doi: 10.1023/a:1020929415443. [DOI] [PubMed] [Google Scholar]
  • [77].Kugaya A, Kagaya A, Uchitomi Y, Yokota N, Yamawaki S. Effect of inter feron-alpha on DOI-induced wet-dog shakes in rats. J Neural Transm. 1996;103:947–955. doi: 10.1007/BF01291785. [DOI] [PubMed] [Google Scholar]
  • [78].Zalcman S, Green-Johnson JM, Murray L, Nance DM, Dyck D, Anisman H, et al. Cytokine-specific central monoamine alterations induced by interleukin-1, -2 and -6. Brain Res. 1994;643:40–49. doi: 10.1016/0006-8993(94)90006-x. [DOI] [PubMed] [Google Scholar]
  • [79].Hurst SM, Collins SM. Mechanism underlying tumor necrosis factor-alpha suppression of norepinephrine release from rat myenteric plexus. Am J Physiol. 1994;266:G1123–1129. doi: 10.1152/ajpgi.1994.266.6.G1123. [DOI] [PubMed] [Google Scholar]
  • [80].Ando T, Dunn AJ. Mouse tumor necrosis factor-alpha increases brain trypt ophan concentrations and norepinephrine metabolism while activating the HPA axis in mice. Neuroimmunomodulation. 1999;6:319–329. doi: 10.1159/000026391. [DOI] [PubMed] [Google Scholar]
  • [81].Moron JA, Zakharova I, Ferrer JV, Merrill GA, Hope B, Lafer EM, et al. Mi togen-activated protein kinase regulates dopamine transporter surface expression and dopamine transport capacity. J Neurosci. 2003;23:8480–8488. doi: 10.1523/JNEUROSCI.23-24-08480.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [82].Wu HQ, Rassoulpour A, Schwarcz R. Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? J Neural Transm. 2007;114:33–41. doi: 10.1007/s00702-006-0562-y. [DOI] [PubMed] [Google Scholar]
  • [83].Shuto H, Kataoka Y, Horikawa T, Fujihara N, Oishi R. Repeated interferon-al pha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res. 1997;747:348–351. doi: 10.1016/s0006-8993(96)01371-6. [DOI] [PubMed] [Google Scholar]
  • [84].Felger JC, Alagbe O, Hu F, Mook D, Freeman AA, Sanchez MM, et al. Effects of interferon-alpha on rhesus monkeys: a nonhuman primate model of cytokine-induced depression. Biol Psychiatry. 2007;62:1324–1333. doi: 10.1016/j.biopsych.2007.05.026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [85].Kitagami T, Yamada K, Miura H, Hashimoto R, Nabeshima T, Ohta T. Mechanism of systemically injected interferon-alpha impeding monoamine biosynthesis in rats: role of nitric oxide as a signal crossing the blood-brain barrier. Brain Res. 2003;978:104–114. doi: 10.1016/s0006-8993(03)02776-8. [DOI] [PubMed] [Google Scholar]
  • [86].McNally L, Bhagwagar Z, Hannestad J. Inflammation, glutamate, and glia in depr ession: a literature review. CNS Spectr. 2008;13:501–510. doi: 10.1017/s1092852900016734. [DOI] [PubMed] [Google Scholar]
  • [87].Viviani B, Bartesaghi S, Gardoni F, Vezzani A, Behrens MM, Bartfai T, et al. In terleukin-1beta enhances NMDA receptor-mediated intracellular calcium increase through activation of the Src family of kinases. J Neurosci. 2003;23:8692–8700. doi: 10.1523/JNEUROSCI.23-25-08692.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [88].Hu S, Sheng WS, Ehrlich LC, Peterson PK, Chao CC. Cytokine effects on glutamate uptake by human astrocytes. Neuroimmunomodulation. 2000;7:153–159. doi: 10.1159/000026433. [DOI] [PubMed] [Google Scholar]
  • [89].Dowben JS, Grant JS, Keltner NL. Ketamine as an alternative treatment for treatme nt-resistant depression. Perspect Psychiatr Care. 2013;49:2–4. doi: 10.1111/ppc.12006. [DOI] [PubMed] [Google Scholar]
  • [90].Mathews DC, Zarate CA., Jr Current status of ketamine and related compounds for de pression. J Clin Psychiatry. 2013;74:516–517. doi: 10.4088/JCP.13ac08382. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [91].Katalinic N, Lai R, Somogyi A, Mitchell PB, Glue P, Loo CK. Ketamine as a new treat ment for depression: a review of its efficacy and adverse effects. Aust N Z J Psychiatry. 2013;47:710–727. doi: 10.1177/0004867413486842. [DOI] [PubMed] [Google Scholar]
  • [92].Howland RH. Ketamine for the treatment of depression. J Psychosoc Nurs Ment Health S erv. 2013;51:11–14. doi: 10.3928/02793695-20121219-01. [DOI] [PubMed] [Google Scholar]
  • [93].Hayley S, Poulter MO, Merali Z, Anisman H. The pathogenesis of clinical depression: s tressor- and cytokine-induced alterations of neuroplasticity. Neuroscience. 2005;135:659–678. doi: 10.1016/j.neuroscience.2005.03.051. [DOI] [PubMed] [Google Scholar]
  • [94].Fuchs E, Czeh B, Kole MH, Michaelis T, Lucassen PJ. Alterations of neuroplasticity in depression: the hippocampus and beyond. Eur Neuropsychopharmacol. 2004;14Suppl5:S481–490. doi: 10.1016/j.euroneuro.2004.09.002. [DOI] [PubMed] [Google Scholar]
  • [95].Carlson PJ, Singh JB, Zarate CA, Jr., Drevets WC, Manji HK. Neural circuitry and neurop lasticity in mood disorders: insights for novel therapeutic targets. NeuroRx. 2006;3:22–41. doi: 10.1016/j.nurx.2005.12.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [96].Sapolsky RM. The possibility of neurotoxicity in the hippocampus in major depression: a primer on neuron death. Biol Psychiatry. 2000;48:755–765. doi: 10.1016/s0006-3223(00)00971-9. [DOI] [PubMed] [Google Scholar]
  • [97].Manji HK, Quiroz JA, Sporn J, Payne JL, Denicoff K, Denicoff N A, et al. Enhancing neuronal plast icity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. 2003;53:707–742. doi: 10.1016/s0006-3223(03)00117-3. [DOI] [PubMed] [Google Scholar]
  • [98].Kaneko N, Kudo K, Mabuchi T, Takemoto K, Fujimaki K, Wati H, et al. Suppression of cell pr oliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology. 2006;31:2619–2626. doi: 10.1038/sj.npp.1301137. [DOI] [PubMed] [Google Scholar]
  • [99].Alboni S, Gibellini L, Montanari C, Benatti C, Benatti S, Tascedda F, et al. N-acetyl-cyste ine prevents toxic oxidative effects induced by IFN-alpha in human neurons. Int J Neuropsychopharmacol. 2013;16:1849–1865. doi: 10.1017/S1461145713000266. [DOI] [PubMed] [Google Scholar]
  • [100].Sapolsky RM, Krey LC, McEwen BS. Prolonged glucocorticoid exposure reduces hippocampal neur on number: implications for aging. J Neurosci. 1985;5:1222–1227. doi: 10.1523/JNEUROSCI.05-05-01222.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [101].McEwen BS. Plasticity of the hippocampus: adaptation to chronic stress and allostatic load. Ann N Y Acad Sci. 2001;933:265–277. doi: 10.1111/j.1749-6632.2001.tb05830.x. [DOI] [PubMed] [Google Scholar]
  • [102].Poo MM. Neurotrophins as synaptic modulators. Nat Rev Neurosci. 2001;2:24–32. doi: 10.1038/35049004. [DOI] [PubMed] [Google Scholar]
  • [103].Patapoutian A, Reichardt LF. Trk receptors: mediators of neurotrophin action. Curr Opin Neurob iol. 2001;11:272–280. doi: 10.1016/s0959-4388(00)00208-7. [DOI] [PubMed] [Google Scholar]
  • [104].Mattson MP, Maudsley S, Martin B. BDNF and 5-HT: a dynamic duo in age-related neuronal plastici ty and neurodegenerative disorders. Trends Neurosci. 2004;27:589–594. doi: 10.1016/j.tins.2004.08.001. [DOI] [PubMed] [Google Scholar]

Articles from Neuroscience Bulletin are provided here courtesy of Springer

RESOURCES